AB Science Publishes Press Releases and Media Mentions

AB Science offers a dedicated news and media section on its website, consolidating its press releases and compiling mentions of the company in the press. This area serves as a key information hub for stakeholders, including investors, researchers, and patient advocacy groups.

The website also provides access to sections on corporate governance, the company's scientific and product pipeline, including details on masitinib for neurodegenerative and inflammatory diseases, and AB8939 for oncology. Information regarding clinical studies and participation is also available.

Furthermore, visitors can navigate to dedicated investor relations pages. These pages contain financial reports, stock information, and details about the company's board of directors and their responsibilities. Information regarding regulated agreements and disclosures are also accessible.

The site is available in multiple languages, including French, and provides contact information and career opportunities. AB Science also directs users to information about their drug Masivet®.